CN111265709A - Pediatric wound protection film for preventing pneumovirus infection and preparation method thereof - Google Patents
Pediatric wound protection film for preventing pneumovirus infection and preparation method thereof Download PDFInfo
- Publication number
- CN111265709A CN111265709A CN202010203786.2A CN202010203786A CN111265709A CN 111265709 A CN111265709 A CN 111265709A CN 202010203786 A CN202010203786 A CN 202010203786A CN 111265709 A CN111265709 A CN 111265709A
- Authority
- CN
- China
- Prior art keywords
- bacterial cellulose
- ribavirin
- membrane
- protection film
- wound protection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/20—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing organic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/24—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/425—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/258—Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
- A61L2300/408—Virucides, spermicides
Abstract
The invention provides a pediatric wound protection film for preventing pneumovirus infection and a preparation method thereof. Firstly, preparing a bacterial cellulose membrane by a fermentation method, then soaking the bacterial cellulose membrane in a ribavirin aqueous solution, and carrying out ultrasonic oscillation treatment for full adsorption to prepare a bacterial cellulose/ribavirin composite membrane with the water content of 5-10%; and finally, preparing a chitosan/quaternary ammonium salt/polyvinyl alcohol mixed spinning solution, adopting a flat plate receiving electrostatic spinning method, taking the bacterial cellulose/ribavirin composite film as a receiving plate of electrostatic spinning, carrying out electrostatic spinning on the spinning solution, then reinforcing, cutting into a preset size, packaging and sterilizing, and preparing the wound protection film compounded by the nano fiber film and the bacterial cellulose/ribavirin composite film. The wound protection film prepared by the invention not only has excellent performance of resisting bacteria and pneumonia virus infection, but also has good biocompatibility, biodegradability and mechanical property.
Description
Technical Field
The invention relates to the field of medical supplies, in particular to a pediatric wound protection film for preventing pneumovirus infection and a preparation method thereof.
Background
In the aspect of anti-infection treatment of pediatric wound surfaces, aiming at the characteristic that the immunity development of children is immature, the protective dressing used for the wound surfaces is basically made of simple sterile gauze, sterilized absorbent cotton, bandages and other natural fibrous materials, can dry the wounds and provides a simple physical barrier for the wounds. However, these protective materials have simple structure and single function, not only do not have the effects of resisting bacteria, virus infection and bacteria, but also cannot provide safe and sterile body surface contact environment for the wound surface recovery process of children, and are easy to breed bacteria and generate peculiar smell. In addition, the body surface of the child is exuberant in secretion, the protective materials have low absorption speed and small absorption amount on sweat stains and dirt generated on the body surface of the child, are easy to reverse seep, are unsmooth in absorption and drainage on exudate at the local part of a wound in the using process, are easy to cause wound infection, and cannot maintain a moist healing environment; when in use, the adhesive is easy to be adhered with wound exudate, secondary injury is caused during replacement, pain is caused, poor wound healing can be caused, and the pain of children is increased.
Therefore, an ideal pediatric wound protection dressing should have the following characteristics: 1) the moisture-keeping and moisture-absorbing performance can absorb excessive seepage of the wound, thereby being beneficial to drainage and simultaneously maintaining the moist environment of the wound; 2) the biocompatibility is good, and the medicine is non-toxic and non-irritant to human bodies; 3) the antibacterial and antiviral wound surface protective agent has good antibacterial and antiviral infection performance, and can effectively prevent wound surface infection; 4) easy to change, not easy to adhere with wound exudate, reducing the damage to the new granulation tissue when changing the medicine and relieving the pain of children.
The invention patent with the application number of CN201910129823.7 discloses an anti-infection dressing for a pediatric wound surface. The preparation method of the dressing comprises the following steps: firstly) preparing polyprenyl zinc modified hyaluronic acid, secondly) preparing quaternary ammonium salt 15 modified chitosan, thirdly) preparing functional quaternary ammonium salt 15 modified chitosan, fourthly) ion exchange, fifthly) preparing surface modified carbon sponge, sixthly) preparing functional composition, and seventhly) preparing and forming dressing. The functional components are formed by compounding the polyprenyl modified hyaluronic acid, the functionalized quaternary ammonium salt 15 modified chitosan and the surface modified carbon sponge, and the prepared paediatric wound surface anti-infection dressing has the advantages of remarkable antibacterial and anti-infection effects and good biocompatibility. However, the preparation method of the dressing is complex in process, does not have the function of resisting virus infection, has limited promotion effect on wound healing, and cannot meet the requirement of practical application.
The invention patent with the application number of CN201710543301.2 discloses a natural material anti-infection dressing block for a pediatric wound surface. The dressing top-down includes anti-infection functional layer and waterproof bottom in proper order, wherein set up at least one kind natural anti-infection material on the anti-infection functional layer, waterproof bottom sets up the lower surface at anti-infection functional layer, natural anti-infection material is chitin, mustard, castor oil, the mixture of one kind or more than two kinds in the horseradish, anti-infection functional layer is inside to include one deck water absorbent resin, and on this water absorbent resin, the lower surface all is with one deck fluff pulp, a plurality of active carbon particles are evenly laid to fluff pulp inside, the fluff pulp upper surface evenly spreads nanometer silver or chitosan granule, be equipped with a plurality of far infrared chips between water absorbent resin and the fluff pulp, anion chip, magnetic chip group. However, the dressing has certain antibacterial and bacteriostatic properties, but does not have the function of resisting virus infection, has poor biocompatibility, and does not greatly improve the performance of promoting wound healing.
The infantile viral pneumonia is a common disease of children and has a certain lethality rate. Viral pneumonia is a pulmonary inflammation caused by viral infection, and can be infected by the direct contact of the wound surface of the skin of children with pneumonia virus. In view of the above, there is a need to develop a pediatric wound protection dressing with anti-pneumovirus infection function, which is used for protecting wound surfaces of children from anti-pneumovirus infection.
Disclosure of Invention
In view of the defects of the prior art, the invention aims to provide a pediatric pneumonia virus infection prevention wound protection film with excellent antibacterial and antiviral infection performance and excellent mechanical performance and a preparation method thereof.
In order to achieve the above object, the present invention provides a method for preparing a wound protection film for preventing pneumovirus infection for pediatrics, comprising the following steps:
s1, preparing a bacterial cellulose membrane protomembrane through fermentation culture, immersing the bacterial cellulose membrane protomembrane into a 2-4% NaOH solution, carrying out hot alkali treatment for 1-4 hours at the temperature of 60-80 ℃, repeatedly carrying out hot alkali treatment for multiple times, then carrying out cleaning treatment to obtain a bacterial cellulose wet membrane, placing the bacterial cellulose wet membrane in an oven at the temperature of 40-60 ℃ for drying treatment until the water content of the bacterial cellulose wet membrane is reduced to 30-50%, and preparing to obtain a bacterial cellulose membrane;
s2, dipping the bacterial cellulose membrane prepared in the step S1 in a ribavirin water solution with a preset concentration, and repeatedly carrying out ultrasonic oscillation treatment for multiple times; after the bacterial cellulose membrane is fully adsorbed, placing the bacterial cellulose membrane subjected to dipping treatment in an oven at 40-60 ℃ for drying treatment to prepare a bacterial cellulose/ribavirin composite membrane with a predetermined water content;
s3, dissolving chitosan powder in an acetic acid solution with the volume fraction of 0.5-1.5%, preparing a chitosan solution with a preset mass-volume concentration, and standing for defoaming; mixing polyvinyl alcohol, quaternary ammonium salt and water, and magnetically stirring for 1-3 hours in water bath heating at 85-95 ℃ until the polyvinyl alcohol is completely dissolved to obtain a polyvinyl alcohol mixed solution; blending the chitosan solution and the polyvinyl alcohol mixed solution according to a predetermined proportion, stirring for 5-6 h at normal temperature, standing and defoaming to obtain a spinning solution; and (4) taking the bacterial cellulose/ribavirin composite film prepared in the step (S2) as a receiving plate for electrostatic spinning, carrying out electrostatic spinning on the spinning solution by adopting a flat plate receiving electrostatic spinning method, then reinforcing, cutting into a preset size, packaging and disinfecting, and preparing the wound protection film compounded by the nano fiber film and the bacterial cellulose/ribavirin composite film.
Preferably, in the aqueous solution of ribavirin described in step S2, the mass-volume concentration of ribavirin is 0.5mg/500mL to 1.0mg/500 mL.
Preferably, in step S2, the bacterial cellulose/ribavirin composite membrane has a water content of 5-10%.
Preferably, in step S3, the chitosan solution has a mass volume concentration of 2-4%.
Preferably, in the polyvinyl alcohol mixed solution of step S3, the mass fraction of the polyvinyl alcohol is 8 to 12 wt%, and the mass fraction of the quaternary ammonium salt polymer is 0.5 to 2 wt%.
Preferably, the volume ratio of the chitosan solution to the polyvinyl alcohol mixed solution is 20-40% to 60-80%.
Preferably, in step S3, the process parameters of the flat plate receiving electrospinning method are as follows: the voltage is 18-22 kV, the spinning speed is 0.5-1.0 mL/h, and the spinning distance is 12-15 cm.
In order to achieve the purpose of the invention, the invention also provides a wound protection film prepared by the preparation method. The wound protection film is formed by compounding a nanofiber film serving as a surface protection layer and a bacterial cellulose/ribavirin composite film serving as a bottom antiviral infection layer.
Preferably, the nanofiber membrane is a chitosan/quaternary ammonium salt/polyvinyl alcohol composite nanofiber membrane prepared by an electrostatic spinning process.
Compared with the prior art, the invention has the beneficial effects that:
1. the invention provides a preparation method of a pediatric wound protection film for preventing pneumonia virus infection, which adopts an immersion method to prepare a bacterial cellulose/ribavirin composite film, belongs to a physical composite method, and mainly combines the bacterial cellulose and ribavirin through the action of hydrogen bonds. The water content is 30-50% of a large amount of free water and bound water existing in the bacterial cellulose membrane, and the bound water is combined with hydroxyl on a molecular chain of the bacterial cellulose membrane through a hydrogen bond effect. When the bacterial cellulose membrane is soaked in the ribavirin aqueous solution, ribavirin molecules can enter a three-dimensional network structure of the bacterial cellulose membrane through diffusion, a part of ribavirin molecules replace the bound water to perform hydrogen bonding with hydroxyl groups in the bacterial cellulose membrane, and other ribavirin molecules exist on the surface and inside of the bacterial cellulose membrane fibers in a free molecular state. Because the ribavirin is a broad-spectrum antiviral nucleoside compound, the bacterial cellulose/ribavirin composite membrane prepared by the invention integrates the excellent performances of the bacterial cellulose membrane and the ribavirin, so that the bacterial cellulose/ribavirin composite membrane not only has a nano-scale fine mesh structure, stronger water retention and moisture retention capacity, excellent biocompatibility and biodegradability, but also has excellent performance of resisting pneumonia virus infection.
2. The pediatric wound protection film for preventing pneumovirus infection is formed by compounding two-layer structures of a nanofiber film and a bacterial cellulose/ribavirin composite film, and has excellent mechanical property, anti-infection property and biocompatibility.
1) The chitosan/quaternary ammonium salt/polyvinyl alcohol composite electrostatic spinning nano-fiber membrane is prepared by introducing chitosan and quaternary ammonium salt antibacterial polymer into polyvinyl alcohol spinning solution, has uniform crystallization and fiber distribution trend and good fiber forming property. The nanofiber membrane is used as a surface protection layer, has protection and antibacterial effects, can effectively prevent invasion of foreign microorganisms, and synergistically promotes the nanofiber membrane to have remarkable antibacterial performance based on the excellent antibacterial performance of chitosan and quaternary ammonium salt, so that the composite membrane at the bottom layer is further effectively protected. And the nanofiber membrane taking the polyvinyl alcohol as the fiber main body integrates the excellent mechanical property of the polyvinyl alcohol and the excellent property of the specific nanometer scale of the nanofiber.
2) The bacterial cellulose/ribavirin composite membrane is used as a bottom antiviral infection layer, can directly contact wound surfaces, has the performance of resisting pneumonia virus infection, has good biocompatibility, exerts the performance of the bacterial cellulose, is beneficial to the adhesion and proliferation of cells and promotes the generation of new tissues; and can also play important functions of moisture absorption and retention, and promote the absorption and drainage of wound exudates. Meanwhile, the bacterial cellulose/ribavirin composite membrane has a certain water content, so that on one hand, the moist microenvironment of the wound surface can be maintained, and the wound healing is promoted. In the second aspect, compared with a dry film, the composite material has better mechanical properties and is not easy to break; compared with a wet film with high water content, the water-based moisture-preserving film has better processing and preserving performance. In the third aspect, in the bacterial cellulose/ribavirin composite membrane, the bacterial cellulose membrane is used as a drug-loading main body, and can slowly release ribavirin when wound surfaces are protected for use, so that the effect of resisting pneumonia virus infection is achieved. In the fourth aspect, the composite film contains a bacterial cellulose structure, so that the moisture healing environment of the wound can be maintained due to the excellent moisture absorption performance of the composite film, the dressing change frequency can be reduced, and the composite film has a good promoting effect on the healing of the wound; before the wound dressing is uncovered, physiological saline is firstly adopted for wetting, so that the wound dressing cannot be adhered to the wound surface, and the occurrence of secondary injury can be effectively avoided.
3) The surface antibacterial protective nanofiber membrane and the bottom antiviral infection layer are mutually compounded, so that the wound care membrane has comprehensive performances of antibacterial and antiviral infection and excellent mechanical properties.
Detailed Description
The technical solutions of the embodiments of the present invention will be described clearly and completely below, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments of the present invention without any inventive step, are within the scope of the present invention.
A preparation method of a pediatric wound protection film for preventing pneumovirus infection comprises the following steps:
s1, preparing a bacterial cellulose membrane protomembrane through fermentation culture, immersing the bacterial cellulose membrane protomembrane into a 2-4% NaOH solution, carrying out hot alkali treatment for 1-4 hours at the temperature of 60-80 ℃, repeatedly carrying out hot alkali treatment for multiple times, then carrying out cleaning treatment to obtain a bacterial cellulose wet membrane, placing the bacterial cellulose wet membrane in an oven at the temperature of 40-60 ℃ for drying treatment until the water content of the bacterial cellulose wet membrane is reduced to 30-50%, and preparing to obtain a bacterial cellulose membrane;
s2, dipping the bacterial cellulose membrane prepared in the step S1 into a ribavirin water solution with a preset concentration, and carrying out ultrasonic oscillation treatment; after the bacterial cellulose membrane is fully adsorbed, placing the bacterial cellulose membrane subjected to dipping treatment in an oven at 40-60 ℃ for drying treatment to prepare a bacterial cellulose/ribavirin composite membrane with a predetermined water content;
s3, dissolving chitosan powder in an acetic acid solution with the volume fraction of 0.5-1.5%, preparing a chitosan solution with a preset mass-volume concentration, and standing for defoaming; mixing polyvinyl alcohol, quaternary ammonium salt and water, and magnetically stirring for 1-3 hours in water bath heating at 85-95 ℃ until the polyvinyl alcohol is completely dissolved to obtain a polyvinyl alcohol mixed solution; blending the chitosan solution and the polyvinyl alcohol mixed solution according to a predetermined proportion, stirring for 5-6 h at normal temperature, standing and defoaming to obtain a spinning solution; and (4) taking the bacterial cellulose/ribavirin composite film prepared in the step (S2) as a receiving plate for electrostatic spinning, carrying out electrostatic spinning on the spinning solution by adopting a flat plate receiving electrostatic spinning method, then reinforcing, cutting into a preset size, packaging and disinfecting, and preparing the wound protection film compounded by the nano fiber film and the bacterial cellulose/ribavirin composite film.
Further, in the aqueous solution of ribavirin described in step S2, the mass-volume concentration of ribavirin is 0.5mg/500mL to 1.0mg/500 mL.
Further, in step S2, the water content of the bacterial cellulose/ribavirin complex film is 5-10%.
Further, in step S3, the chitosan solution has a mass volume concentration of 2-4%.
Further, in the polyvinyl alcohol mixed solution of step S3, the mass fraction of the polyvinyl alcohol is 8 to 12 wt%, and the mass fraction of the quaternary ammonium salt polymer is 0.5 to 2 wt%.
Furthermore, the volume ratio of the chitosan solution to the polyvinyl alcohol mixed solution is 20-40% to 60-80%.
Further, in step S3, the process parameters of the flat plate receiving electrospinning method are: the voltage is 18-22 kV, the spinning speed is 0.5-1.0 mL/h, and the spinning distance is 12-15 cm.
Further, the nanofiber membrane is a chitosan/quaternary ammonium salt/polyvinyl alcohol composite nanofiber membrane prepared through an electrostatic spinning process.
The following provides a detailed description of the preparation method of the pediatric wound protection film for preventing pneumovirus infection through specific examples.
Example 1
A preparation method of a pediatric wound protection film for preventing pneumovirus infection comprises the following steps:
s1, preparing a bacterial cellulose membrane protomembrane through fermentation culture, immersing the protomembrane into a 4% NaOH solution, treating the protomembrane for 3 hours at 80 ℃, repeatedly washing the protomembrane for multiple times by using deionized water to remove residual culture medium and thalli on the protomembrane to obtain a semitransparent bacterial cellulose wet membrane, drying the wet bacterial cellulose membrane in a 50 ℃ drying oven until the water content of the wet bacterial cellulose membrane is reduced to 40%, and preparing the bacterial cellulose membrane;
s2, dipping the bacterial cellulose membrane prepared in the step S1 in a ribavirin aqueous solution with the concentration of 1mg/500mL, carrying out ultrasonic oscillation treatment for 3 hours at an interval of 1 hour, and repeating the ultrasonic oscillation treatment for three times; after the bacterial cellulose membrane is fully adsorbed, drying the bacterial cellulose membrane after the dipping treatment in an oven at 50 ℃ to prepare a bacterial cellulose/ribavirin composite membrane with the water content of 10%;
s3, dissolving chitosan powder in an acetic acid solution with the volume fraction of 1.0% to prepare a chitosan solution with the mass volume concentration of 3%, and standing for defoaming; mixing polyvinyl alcohol, quaternary ammonium salt and water, and magnetically stirring for 2 hours in water bath heating at 90 ℃ until the polyvinyl alcohol is completely dissolved to obtain a polyvinyl alcohol mixed solution, wherein the mass fraction of the polyvinyl alcohol is 10 wt%, and the mass fraction of the quaternary ammonium salt is 1 wt%. Mixing the chitosan solution and the polyvinyl alcohol mixed solution according to a ratio of 30%: blending at the proportion of 70 percent, stirring for 6 hours at normal temperature, standing and defoaming to prepare the spinning solution. And (2) taking the bacterial cellulose/ribavirin composite membrane prepared in the step (S2) as a receiving plate of electrostatic spinning, and carrying out electrostatic spinning on the spinning solution by adopting a flat plate receiving electrostatic spinning method, wherein the spinning process parameters are as follows: the voltage is 20kV, the spinning speed is 0.5mL/h, and the spinning distance is 15 cm. And then reinforcing and cutting the wound protection film into the size of 5cm x5cm, and then packaging and sterilizing the wound protection film to obtain the wound protection film compounded by the nanofiber film and the bacterial cellulose/ribavirin composite film.
The wound protection film prepared in example 1 was tested, and the results of product performance tests according to the test methods of "anti-viral textile test standard" (ISO18184:2014) and "GB/T20944.3-2008 fabric antibacterial performance" were as follows: the wound protection film has the anti-influenza virus rate of 93.5 percent, the anti-adenovirus rate of 92.9 percent, the anti-pneumonia virus rate of 94.8 percent, the anti-staphylococcus aureus rate of 99.2 percent and the anti-escherichia coli rate of 99.0 percent.
Comparative example 1
The difference from example 1 is that: the immersion treatment of the aqueous solution of ribavirin is not performed in step S2, and the other steps are the same as in example 1 and will not be described again.
The wound protection film prepared in comparative example 1 was tested according to the method described above: the wound protection film does not have the performance of resisting pneumonia virus infection, the ratio of resisting staphylococcus aureus is 99.0%, and the ratio of resisting escherichia coli is 98.8%.
Example 2
A preparation method of a pediatric wound protection film for preventing pneumovirus infection comprises the following steps:
s1, preparing a bacterial cellulose membrane protomembrane through fermentation culture, immersing the protomembrane into a 4% NaOH solution, treating the protomembrane for 4 hours at 70 ℃, repeatedly washing the protomembrane for multiple times by using deionized water to remove residual culture medium and thalli on the protomembrane to obtain a semitransparent bacterial cellulose wet membrane, drying the wet bacterial cellulose membrane in a 60 ℃ drying oven until the water content of the wet bacterial cellulose membrane is reduced to 50%, and preparing the bacterial cellulose membrane;
s2, dipping the bacterial cellulose membrane prepared in the step S1 in a ribavirin aqueous solution with the concentration of 0.5mg/500mL, carrying out ultrasonic oscillation treatment for 3 hours at an interval of 1 hour, and repeating the ultrasonic oscillation treatment for three times; after the bacterial cellulose membrane is fully adsorbed, drying the bacterial cellulose membrane after the dipping treatment in an oven at 50 ℃ to prepare a bacterial cellulose/ribavirin composite membrane with the water content of 10%;
s3, dissolving chitosan powder in an acetic acid solution with the volume fraction of 1.0% to prepare a chitosan solution with the mass volume concentration of 3%, and standing for defoaming; mixing polyvinyl alcohol, quaternary ammonium salt and water, and magnetically stirring for 2 hours in water bath heating at 90 ℃ until the polyvinyl alcohol is completely dissolved to obtain a polyvinyl alcohol mixed solution, wherein the mass fraction of the polyvinyl alcohol is 10 wt%, and the mass fraction of the quaternary ammonium salt is 1 wt%. Mixing the chitosan solution and the polyvinyl alcohol mixed solution according to a ratio of 30%: blending at the proportion of 70 percent, stirring for 6 hours at normal temperature, standing and defoaming to prepare the spinning solution. And (2) taking the bacterial cellulose/ribavirin composite membrane prepared in the step (S2) as a receiving plate of electrostatic spinning, and carrying out electrostatic spinning on the spinning solution by adopting a flat plate receiving electrostatic spinning method, wherein the spinning process parameters are as follows: the voltage is 20kV, the spinning speed is 0.5mL/h, and the spinning distance is 15 cm. And then reinforcing, cutting into the size of 7.5cm x5cm, packaging and sterilizing to obtain the wound protection film compounded by the nanofiber film and the bacterial cellulose/ribavirin composite film.
The wound protection film prepared in example 2 was tested: the wound protection film has the anti-influenza virus rate of 90.1 percent, the anti-adenovirus rate of 87.4 percent, the anti-pneumonia virus rate of 92.3 percent, the anti-staphylococcus aureus rate of 99.0 percent and the anti-escherichia coli rate of 99.0 percent. Compared with example 1, the test result shows that, in step S2, the concentration of the ribavirin aqueous solution influences the antiviral performance of the wound protection film. Within the range of ensuring the medication safety of children, the increase of the concentration of the ribavirin aqueous solution improves the anti-pneumonia virus infection performance of the wound protective film.
Example 3
A preparation method of a pediatric wound protection film for preventing pneumovirus infection comprises the following steps:
s1, preparing a bacterial cellulose membrane protomembrane through fermentation culture, immersing the protomembrane into a 4% NaOH solution, treating the protomembrane for 4 hours at 70 ℃, repeatedly washing the protomembrane for multiple times by using deionized water to remove residual culture medium and thalli on the protomembrane to obtain a semitransparent bacterial cellulose wet membrane, drying the wet bacterial cellulose membrane in a 60 ℃ drying oven until the water content of the wet bacterial cellulose membrane is reduced to 50%, and preparing the bacterial cellulose membrane;
s2, dipping the bacterial cellulose membrane prepared in the step S1 in a ribavirin aqueous solution with the concentration of 1.0mg/500mL, carrying out ultrasonic oscillation treatment for 3 hours at an interval of 1 hour, and repeating the ultrasonic oscillation treatment for three times; after the bacterial cellulose membrane is fully adsorbed, drying the bacterial cellulose membrane after the dipping treatment in an oven at 50 ℃ to prepare a bacterial cellulose/ribavirin composite membrane with the water content of 5%;
s3, dissolving chitosan powder in an acetic acid solution with the volume fraction of 1.0% to prepare a chitosan solution with the mass volume concentration of 3%, and standing for defoaming; mixing polyvinyl alcohol, quaternary ammonium salt and water, and magnetically stirring for 2 hours in water bath heating at 90 ℃ until the polyvinyl alcohol is completely dissolved to obtain a polyvinyl alcohol mixed solution, wherein the mass fraction of the polyvinyl alcohol is 10 wt%, and the mass fraction of the quaternary ammonium salt is 1.5 wt%. Mixing the chitosan solution and the polyvinyl alcohol mixed solution according to a ratio of 40%: blending at the proportion of 60 percent, stirring for 6 hours at normal temperature, standing and defoaming to prepare the spinning solution. And (2) taking the bacterial cellulose/ribavirin composite membrane prepared in the step (S2) as a receiving plate of electrostatic spinning, and carrying out electrostatic spinning on the spinning solution by adopting a flat plate receiving electrostatic spinning method, wherein the spinning process parameters are as follows: the voltage is 20kV, the spinning speed is 0.5mL/h, and the spinning distance is 15 cm. And then reinforcing, cutting into the size of 7.5cm x7.5cm, packaging and sterilizing to obtain the wound protection film compounded by the nanofiber film and the bacterial cellulose/ribavirin composite film.
The wound protection film prepared in example 3 was tested: the wound protection film has the anti-influenza virus rate of 91.8 percent, the anti-adenovirus rate of 89.3 percent, the anti-pneumonia virus rate of 92.0 percent, the anti-staphylococcus aureus rate of 99.5 percent and the anti-escherichia coli rate of 99.4 percent. Compared with the example 1, the detection result shows that the water content of the bacterial cellulose/ribavirin composite membrane in the step S2 has a certain influence on the antiviral performance of the wound protection membrane. The water content is low, the speed of the wound protective film releasing the drug ribavirin is low, the release amount is low, and the effect of resisting pneumonia virus infection is influenced to a certain extent. Meanwhile, the antibacterial performance of the wound protection film can be improved due to the increase of the proportion of the chitosan to the quaternary ammonium salt.
In conclusion, the invention provides a pediatric wound protection film for preventing pneumovirus infection and a preparation method thereof. Firstly, preparing a bacterial cellulose membrane by a fermentation method, then soaking the bacterial cellulose membrane in a ribavirin aqueous solution, and carrying out ultrasonic oscillation treatment for full adsorption to prepare a bacterial cellulose/ribavirin composite membrane with the water content of 5-10%; and finally, preparing a chitosan/quaternary ammonium salt/polyvinyl alcohol mixed spinning solution, adopting a flat plate receiving electrostatic spinning method, taking the bacterial cellulose/ribavirin composite film as a receiving plate of electrostatic spinning, carrying out electrostatic spinning on the spinning solution, then reinforcing, cutting into a preset size, packaging and sterilizing, and preparing the wound protection film compounded by the nano fiber film and the bacterial cellulose/ribavirin composite film. The wound protection film prepared by the invention not only has excellent performance of resisting bacteria and pneumonia virus infection, but also has good biocompatibility, biodegradability and mechanical property.
Finally, it should be noted that: the above examples are only intended to illustrate the technical solution of the present invention, but not to limit it; although the present invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some or all of the technical features may be equivalently replaced; and the modifications or the substitutions do not make the essence of the corresponding technical solutions deviate from the technical solutions of the embodiments of the present invention.
Claims (9)
1. A preparation method of a pediatric wound protection film for preventing pneumovirus infection is characterized by comprising the following steps: the method comprises the following steps:
s1, preparing a bacterial cellulose membrane protomembrane through fermentation culture, immersing the bacterial cellulose membrane protomembrane into a 2-4% NaOH solution, carrying out hot alkali treatment for 1-4 hours at the temperature of 60-80 ℃, repeatedly carrying out hot alkali treatment for multiple times, then carrying out cleaning treatment to obtain a bacterial cellulose wet membrane, placing the bacterial cellulose wet membrane in an oven at the temperature of 40-60 ℃ for drying treatment until the water content of the bacterial cellulose wet membrane is reduced to 30-50%, and preparing to obtain a bacterial cellulose membrane;
s2, dipping the bacterial cellulose membrane prepared in the step S1 in a ribavirin water solution with a preset concentration, and repeatedly carrying out ultrasonic oscillation treatment for multiple times; after the bacterial cellulose membrane is fully adsorbed, placing the bacterial cellulose membrane subjected to dipping treatment in an oven at 40-60 ℃ for drying treatment to prepare a bacterial cellulose/ribavirin composite membrane with a predetermined water content;
s3, dissolving chitosan powder in an acetic acid solution with the volume fraction of 0.5-1.5%, preparing a chitosan solution with a preset mass-volume concentration, and standing for defoaming; mixing polyvinyl alcohol, quaternary ammonium salt and water, and magnetically stirring for 1-3 hours in water bath heating at 85-95 ℃ until the polyvinyl alcohol is completely dissolved to obtain a polyvinyl alcohol mixed solution; blending the chitosan solution and the polyvinyl alcohol mixed solution according to a predetermined proportion, stirring for 5-6 h at normal temperature, standing and defoaming to obtain a spinning solution; and (4) taking the bacterial cellulose/ribavirin composite film prepared in the step (S2) as a receiving plate for electrostatic spinning, carrying out electrostatic spinning on the spinning solution by adopting a flat plate receiving type electrostatic spinning method, then reinforcing and cutting the spinning solution into a preset size, and then packaging and disinfecting the spinning solution to prepare the wound protection film compounded by the nano fiber film and the bacterial cellulose/ribavirin composite film.
2. The method for preparing a pediatric wound protection film for preventing pneumovirus infection according to claim 1, wherein the method comprises the following steps: in the aqueous solution of ribavirin described in step S2, the mass-volume concentration of ribavirin is 0.5mg/500 mL-1.0 mg/500 mL.
3. The method for preparing a pediatric wound protection film for preventing pneumovirus infection according to claim 1, wherein the method comprises the following steps: in step S2, the water content of the bacterial cellulose/ribavirin composite membrane is 5-10%.
4. The method for preparing a pediatric wound protection film for preventing pneumovirus infection according to claim 1, wherein the method comprises the following steps: in step S3, the chitosan solution has a mass volume concentration of 2-4%.
5. The method for preparing a pediatric wound protection film for preventing pneumovirus infection according to claim 1, wherein the method comprises the following steps: in the polyvinyl alcohol mixed solution of step S3, the mass fraction of the polyvinyl alcohol is 8 to 12 wt%, and the mass fraction of the quaternary ammonium salt polymer is 0.5 to 2 wt%.
6. The method for preparing a pediatric wound protection film for preventing pneumovirus infection according to claim 1, wherein the method comprises the following steps: the volume ratio of the chitosan solution to the polyvinyl alcohol mixed solution is 20-40% to 60-80%.
7. The method for preparing a pediatric wound protection film for preventing pneumovirus infection according to claim 1, wherein the method comprises the following steps: in step S3, the process parameters of the flat plate receiving electrospinning method are as follows: the voltage is 18-22 kV, the spinning speed is 0.5-1.0 mL/h, and the spinning distance is 12-15 cm.
8. A wound protection film prepared by the preparation method of the pediatric wound protection film for preventing pneumovirus infection, which is described in any one of claims 1 to 7, and is characterized in that: the wound protection film is formed by compounding a nanofiber film serving as a surface protection layer and a bacterial cellulose/ribavirin composite film serving as a bottom antiviral infection layer.
9. The wound protection film of claim 8, wherein: the nanofiber membrane is a chitosan/quaternary ammonium salt/polyvinyl alcohol composite nanofiber membrane prepared by an electrostatic spinning process.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010203786.2A CN111265709A (en) | 2020-03-20 | 2020-03-20 | Pediatric wound protection film for preventing pneumovirus infection and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010203786.2A CN111265709A (en) | 2020-03-20 | 2020-03-20 | Pediatric wound protection film for preventing pneumovirus infection and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111265709A true CN111265709A (en) | 2020-06-12 |
Family
ID=70991742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010203786.2A Pending CN111265709A (en) | 2020-03-20 | 2020-03-20 | Pediatric wound protection film for preventing pneumovirus infection and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111265709A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113384736A (en) * | 2021-06-25 | 2021-09-14 | 东华大学 | Pullulan-zinc oxide hybrid nanofiber/bacterial cellulose composite functional dressing and preparation method thereof |
| CN114763628A (en) * | 2021-01-13 | 2022-07-19 | 生纳科技(上海)有限公司 | Antiviral nanofiber and preparation method thereof |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0650373A1 (en) * | 1992-06-29 | 1995-05-03 | C V Lab Ltd | Sustained release alginate fibre and process for the preparation thereof. |
| CN101013127A (en) * | 2007-01-05 | 2007-08-08 | 山东省疾病预防控制中心 | Foodstuff coliform group bacteria rapid detecting paper |
| CN102552965A (en) * | 2012-01-17 | 2012-07-11 | 东华大学 | Method for preparing nano-cellulose antibacterial composite material through on-line culture |
| US20130280303A1 (en) * | 2012-04-19 | 2013-10-24 | Warsaw Orthopedic, Inc. | Bone delivery system having a therapeutic agent |
| CN103480027A (en) * | 2012-06-11 | 2014-01-01 | 钟春燕 | Preparation method of bacterial cellulose composite chitosan fiber moist dressing |
| CN105754125A (en) * | 2016-03-02 | 2016-07-13 | 山东纳美德生物科技有限公司 | Bacterial cellulose dry film as well as preparation method and application thereof |
| CN106132447A (en) * | 2013-12-30 | 2016-11-16 | 芬欧汇川集团 | Bio-medical instrument |
| CN106267310A (en) * | 2016-08-16 | 2017-01-04 | 仇颖莹 | A kind of preparation method of composite bacterial cellulose medical dressing |
| CN108836283A (en) * | 2018-04-17 | 2018-11-20 | 六盘水市人民医院 | It is a kind of based on the Respiratory Medicine of big data patient monitor control method |
-
2020
- 2020-03-20 CN CN202010203786.2A patent/CN111265709A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0650373A1 (en) * | 1992-06-29 | 1995-05-03 | C V Lab Ltd | Sustained release alginate fibre and process for the preparation thereof. |
| CN101013127A (en) * | 2007-01-05 | 2007-08-08 | 山东省疾病预防控制中心 | Foodstuff coliform group bacteria rapid detecting paper |
| CN102552965A (en) * | 2012-01-17 | 2012-07-11 | 东华大学 | Method for preparing nano-cellulose antibacterial composite material through on-line culture |
| US20130280303A1 (en) * | 2012-04-19 | 2013-10-24 | Warsaw Orthopedic, Inc. | Bone delivery system having a therapeutic agent |
| CN103480027A (en) * | 2012-06-11 | 2014-01-01 | 钟春燕 | Preparation method of bacterial cellulose composite chitosan fiber moist dressing |
| CN106132447A (en) * | 2013-12-30 | 2016-11-16 | 芬欧汇川集团 | Bio-medical instrument |
| CN105754125A (en) * | 2016-03-02 | 2016-07-13 | 山东纳美德生物科技有限公司 | Bacterial cellulose dry film as well as preparation method and application thereof |
| CN106267310A (en) * | 2016-08-16 | 2017-01-04 | 仇颖莹 | A kind of preparation method of composite bacterial cellulose medical dressing |
| CN108836283A (en) * | 2018-04-17 | 2018-11-20 | 六盘水市人民医院 | It is a kind of based on the Respiratory Medicine of big data patient monitor control method |
Non-Patent Citations (1)
| Title |
|---|
| NAVID GOODARZI ET AL.: "Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Ribavirin", 《JOURNAL OF PHARMACEUTICAL SCIENCES》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114763628A (en) * | 2021-01-13 | 2022-07-19 | 生纳科技(上海)有限公司 | Antiviral nanofiber and preparation method thereof |
| CN113384736A (en) * | 2021-06-25 | 2021-09-14 | 东华大学 | Pullulan-zinc oxide hybrid nanofiber/bacterial cellulose composite functional dressing and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1221984B1 (en) | Wound care device comprising chitosan | |
| EP1859816B1 (en) | The preparing method and the use of antiseptic medical dressing | |
| RU2669557C2 (en) | Absorbing material | |
| FI115608B (en) | wound dressing | |
| US20070104769A1 (en) | Bioabsorbable hemostatic gauze | |
| JPH08505790A (en) | Trauma bandage | |
| CN103550817B (en) | A kind of Bacterial cellulose/shitosan composite sponge dressing and preparation method thereof | |
| RU2422133C1 (en) | Hydrophylic gel, method of its obtaining (versions), wound covering and based on it bandage means | |
| CN103933602A (en) | Preparation method of chitosan-based drug-loading composite antibacterial superfine fiber membrane | |
| CN102552964B (en) | Nano silver chitosan composite antibacterial composition, adhesive bandage and preparation method of adhesive bandage | |
| WO2007056066A2 (en) | Bioabsorbable hemostatic gauze | |
| CN112315660B (en) | Biodegradable nanofiber medical bandage and preparation method thereof | |
| CN106377791A (en) | Bamboo alginate functional dressing and preparation method thereof | |
| CN111265709A (en) | Pediatric wound protection film for preventing pneumovirus infection and preparation method thereof | |
| BRPI0115627B1 (en) | Method to reduce bacterial growth on an unbraided substrate | |
| CN107296975A (en) | A kind of antibacterial anti hemorrhagic based composite dressing for medical use and preparation method thereof | |
| CN101537204B (en) | Medical nanometer antibacterial composite dressing and method for preparing same | |
| CN102921035A (en) | Antiseptic dressing for deep infected wounds | |
| CN113975447A (en) | Antibacterial alginate dressing and preparation method and application thereof | |
| CN104383585A (en) | Three-dimensional nanocomposite adhesive bandage as well as preparation method and use method thereof | |
| Chellamani et al. | Chitosan treated textile substrates for wound care applications | |
| CN109432479B (en) | Antibacterial hemostatic hydrocolloid oily yarn and preparation method thereof | |
| CN107080858A (en) | A kind of wound repair plural gel and preparation method thereof | |
| CN114073786A (en) | Liquid-absorbing antibacterial 3D nanofiber composite medical dressing and preparation method thereof | |
| CN103174017B (en) | Sodium alginate oxide modified chitosan fiber and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 553000 Liupanshui City People's Hospital, 56 Zijin Mountain West Road, Zhongshan District, Liupanshui, Guizhou Applicant after: Chen Chuanhua Address before: 250014 no.16992, Jingshi Road, Lixia District, Jinan City, Shandong Province Applicant before: Chen Chuanhua |
|
| CB02 | Change of applicant information | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200612 |
|
| RJ01 | Rejection of invention patent application after publication |